Innovus Pharmaceuticals Inc (INNV) 0.2280 $INNV
Innovus Pharmaceuticals Well Capitalized With the Closing of $1.5M in Financing From Institutional Investors
Marketwired - Wed Jul 06, 5:05AM CDT
Money Raised to Fast Track the Move to Being Cash Flow Positive in 2016
SECFilings.com Examines Innovus Pharmaceuticals' (INNV) Position in Multi-Billion Dollar Female Sexual Dysfunction Market
Marketwire Canada - Tue Jun 21, 8:01AM CDT
REDONDO BEACH, CA--(Marketwired - Jun 21, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a look at the underserved Female Sexual Interest Arousal Dysfunction (FSI/AD) market and Innovus Pharmaceuticals' (OTCQB: INNV) clinically proven over-the-counter treatment, Zestra®.
Innovus Pharmaceuticals Announces Successful Top Line Results From RecalMax in Memory, Processing Speed and Thought Maintenance
Marketwired - Mon Jun 13, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 13, 2016) - Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter ("OTC"
and consumer products for men's and women's health, vitality and respiratory diseases, announced today that the Company's top line results from its RecalMax™ U.S. four month human survey use clinical trial in people with low memory and learning.
Innovus Pharma (INNV)'s Vesele Could Be the Best Complementary Product for Viagra and Cialis's $3.2 Billion Dollar Erectile Dysfunction Market
Marketwire Canada - Thu Jun 09, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 9, 2016) - Innovus Pharma (OTCQB: INNV) -- The global erectile dysfunction drug market is expected to reach $3.2 billion USD by 2022 according to a new report by Grand View Research Inc. Male sexual dysfunction has become a multi-billion-dollar market fueled by sales of erectile dysfunction drugs like Viagra and Cialis. In fact, Pfizer Inc.'s Viagra surpassed $1 billion in sales during its first year despite having lower than usual third-party coverage. The drug has consistently surpassed $1 billion per year in sales since its launch and even briefly reached above the $2 billion mark back in 2012 despite growing competition.
PFE: 35.77 (-0.09)
Innovus Pharma Announces the Filing of the Product Licenses for Zestra, Zestra Glide, EjectDelay and Sensum+ With the Indian FDA (Directorate General of Health Services) by Its Partner Khandelwal Laboratories
Marketwire Canada - Tue Jun 07, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 7, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma" (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories filed the product licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® with the Indian FDA, The Drugs Controller General (India) and the Directorate General of Health Services to commercialize the products in India.
Innovus Pharma to Request Regulatory Guidance for Filing for Its FlutiCare Product in Europe for the Treatment of Allergic Rhinitis
Marketwired - Thu Jun 02, 9:18AM CDT
Innovus (INNV) Brings Leading Nasal Steroid From Rx to OTC
Innovus (INNV) Brings Leading Nasal Steroid From Rx to OTC
Marketwire Canada - Wed Jun 01, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 1, 2016) - Innovus Pharmaceuticals Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative, and effective over-the-counter medicine and consumer care products, plans to launch a new product into a multi-billion dollar market in the near-term. After acquiring over-the-counter rights to FlutiCare™ -- a leading prescription nasal steroid -- in February 2015, the company expects to receive regulatory approval later this year.
Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision
Marketwired - Tue May 31, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma" (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles. Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.
Innovus Pharma Signs Exclusive License and Distribution Agreement With BroadMed for EjectDelay in Lebanon
Marketwire Canada - Wed May 25, 5:05AM CDT
SAN DIEGO, CA--(Marketwired - May 25, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma" (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases today announced today that it has entered into an exclusive license and distribution agreement with BroadMedSAL, a Lebanese company ("BroadMed" under which Innovus Pharma granted to BroadMed an exclusive license to market and sell Innovus product EjectDelay® indicated for treatment of premature ejaculation in Lebanon. Under the agreement, Innovus Pharma is eligible to receive up to $6.2 million in upfront and sales milestone payments plus transfer price.
Innovus Pharma Joins AbbVie Inc. and Eli Lilly & Co. in the Race for the $3 Billion Testosterone Replacement Market
Marketwired - Tue May 24, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - May 24, 2016) - Innovus Pharmaceuticals, Inc. (OTCQB: INNV), a provider of over-the-counter and consumer products for men and women's health, vitality, and respiratory diseases, recently acquired Beyond Human for a cash purchase price of $630,000. The acquisition provided the company with natural testosterone booster supplements, including Beyond T Human® and Human Growth Agent HGA® that generated $2.2 million in revenue and $400,000 in profit last year.
LLY: 79.32 (-0.70), ABBV: 63.43 (+0.06)
Innovus Pharmaceuticals Well Capitalized With the Closing of $1.5M in Financing From Institutional Investors
Marketwired - Wed Jul 06, 5:05AM CDT
Money Raised to Fast Track the Move to Being Cash Flow Positive in 2016
SECFilings.com Examines Innovus Pharmaceuticals' (INNV) Position in Multi-Billion Dollar Female Sexual Dysfunction Market
Marketwire Canada - Tue Jun 21, 8:01AM CDT
REDONDO BEACH, CA--(Marketwired - Jun 21, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, takes a look at the underserved Female Sexual Interest Arousal Dysfunction (FSI/AD) market and Innovus Pharmaceuticals' (OTCQB: INNV) clinically proven over-the-counter treatment, Zestra®.
Innovus Pharmaceuticals Announces Successful Top Line Results From RecalMax in Memory, Processing Speed and Thought Maintenance
Marketwired - Mon Jun 13, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 13, 2016) - Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter ("OTC"
and consumer products for men's and women's health, vitality and respiratory diseases, announced today that the Company's top line results from its RecalMax™ U.S. four month human survey use clinical trial in people with low memory and learning. Innovus Pharma (INNV)'s Vesele Could Be the Best Complementary Product for Viagra and Cialis's $3.2 Billion Dollar Erectile Dysfunction Market
Marketwire Canada - Thu Jun 09, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 9, 2016) - Innovus Pharma (OTCQB: INNV) -- The global erectile dysfunction drug market is expected to reach $3.2 billion USD by 2022 according to a new report by Grand View Research Inc. Male sexual dysfunction has become a multi-billion-dollar market fueled by sales of erectile dysfunction drugs like Viagra and Cialis. In fact, Pfizer Inc.'s Viagra surpassed $1 billion in sales during its first year despite having lower than usual third-party coverage. The drug has consistently surpassed $1 billion per year in sales since its launch and even briefly reached above the $2 billion mark back in 2012 despite growing competition.
PFE: 35.77 (-0.09)
Innovus Pharma Announces the Filing of the Product Licenses for Zestra, Zestra Glide, EjectDelay and Sensum+ With the Indian FDA (Directorate General of Health Services) by Its Partner Khandelwal Laboratories
Marketwire Canada - Tue Jun 07, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 7, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
(OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced today that its partner Khandelwal Laboratories filed the product licenses for Zestra®, Zestra Glide®, EjectDelay® and Sensum+® with the Indian FDA, The Drugs Controller General (India) and the Directorate General of Health Services to commercialize the products in India. Innovus Pharma to Request Regulatory Guidance for Filing for Its FlutiCare Product in Europe for the Treatment of Allergic Rhinitis
Marketwired - Thu Jun 02, 9:18AM CDT
Innovus (INNV) Brings Leading Nasal Steroid From Rx to OTC
Innovus (INNV) Brings Leading Nasal Steroid From Rx to OTC
Marketwire Canada - Wed Jun 01, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - Jun 1, 2016) - Innovus Pharmaceuticals Inc. (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative, and effective over-the-counter medicine and consumer care products, plans to launch a new product into a multi-billion dollar market in the near-term. After acquiring over-the-counter rights to FlutiCare™ -- a leading prescription nasal steroid -- in February 2015, the company expects to receive regulatory approval later this year.
Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision
Marketwired - Tue May 31, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
(OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles. Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug. Innovus Pharma Signs Exclusive License and Distribution Agreement With BroadMed for EjectDelay in Lebanon
Marketwire Canada - Wed May 25, 5:05AM CDT
SAN DIEGO, CA--(Marketwired - May 25, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma"
(OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases today announced today that it has entered into an exclusive license and distribution agreement with BroadMedSAL, a Lebanese company ("BroadMed" under which Innovus Pharma granted to BroadMed an exclusive license to market and sell Innovus product EjectDelay® indicated for treatment of premature ejaculation in Lebanon. Under the agreement, Innovus Pharma is eligible to receive up to $6.2 million in upfront and sales milestone payments plus transfer price. Innovus Pharma Joins AbbVie Inc. and Eli Lilly & Co. in the Race for the $3 Billion Testosterone Replacement Market
Marketwired - Tue May 24, 5:00AM CDT
SAN DIEGO, CA--(Marketwired - May 24, 2016) - Innovus Pharmaceuticals, Inc. (OTCQB: INNV), a provider of over-the-counter and consumer products for men and women's health, vitality, and respiratory diseases, recently acquired Beyond Human for a cash purchase price of $630,000. The acquisition provided the company with natural testosterone booster supplements, including Beyond T Human® and Human Growth Agent HGA® that generated $2.2 million in revenue and $400,000 in profit last year.
LLY: 79.32 (-0.70), ABBV: 63.43 (+0.06)
